louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04464824: Study of the Preventable Passage of Patients Over 75 Years of Age to the Emergency Room of the CHRU of Nancy
Official title: Study of the Preventable Passage of Patients Over 75 Years of Age to the Emergency Room of the CHRU of Nancy
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Emergencies Elderly
Lead sponsor: Central Hospital, Nancy, France
Sponsor class: OTHER
First posted: 2020-07-09
Enrollment: 1573
Sex: ALL
Minimum age (years): 75
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: - Patients over 75 years of age, with a visit to the emergency department between April 1, 2019 and September 30, 2019, with a non-hospitalization at the end of their visit to the emergency department.

Brief summary: The adult emergency service of the Nancy CHRU welcomes an average of 135 visits per day. Approximately 18% are patients over 75 years old, among them 45% go home at the end of their care. The mobile geriatric liaison team intervenes with these patients at the request of the emergency doctors before they return home in order to identify their fragility and implement appropriate measures.

We wish to know the characteristics of these avoidable passages in order to propose preventive measures upstream of these passages. To do this, we need to know the characteristics of those patients with an avoidable passage.


Eligibility criteria: Inclusion Criteria:

* age\>=75 years old
* admitted at emergency room between first april 2019 and 30 september 2019
* outpatients

Exclusion Criteria:

* inpatients
* discharged patients
* patients discharged against medical advice
* patients brought by police

Primary outcomes:
measure: characteristics of preventable passages to the emergency room of the Nancy CHRU in the population over 75 years old
timeFrame: the day of the admission at emergency room
Secondary outcomes:
Other outcomes:
Locations:
city: Nancy
country: France
facility: CHRU de Nancy
Study officials:
References:
Clinical trial NCT05109624: Is Prolonged Period of Prone Position Effective and Safe in Mechanically Ventilated Patients With SARS-COV-2?
Official title: Is Prolonged Period of Prone Position Effective and Safe in Mechanically Ventilated Patients With SARS-COV-2? A Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: COVID-19 Acute Respiratory Distress Syndrome
Lead sponsor: Ain Shams University
Sponsor class: OTHER
First posted: 2021-11-05
Enrollment: 52
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: the aim of the study is to assess safety and efficacy of prone position ventilation beyond the usual 16 hrs in patients with SARS-COV-2


Eligibility criteria: Inclusion Criteria:

* - American Society of Anesthesiologists (ASA) physical status II- III.
* Sex (male and females).
* Age 18 -80 years.
* Sever adult respiratory distress (ARDS) (defined as a PaO2:FiO2 ratio of \<150 mm Hg, with a fraction of inspired oxygen (FiO2) of ≥0.6, a positive end expiratory pressure (PEEP) of ≥5 CmH2O, and a tidal volume of 6 ml/Kg of predicted body weight
* mechanical ventilation for less than 36 hours

Exclusion Criteria:

* - Contraindication for prone positioning

  * increased intracranial tension.
  * face trauma or surgery.
  * Recent Deep venous thrombosis
  * Unstable spine, femur, or pelvic fractures
  * Mean arterial pressure \< 65 mm Hg
  * Pregnant women
  * Pneumothorax
  * Prone positioning before inclusion
* Those returned to supine position before completing the session time

Primary outcomes:
measure: rate of successful weaning
timeFrame: 28 days
measure: Incidence of complications
timeFrame: 28 days
Secondary outcomes:
measure: Efficacy of oxygenation
timeFrame: 28 days
Other outcomes:
Locations:
city: Cairo
country: Egypt
facility: Ain Shams University hospitals
Study officials:
References:
Clinical trial NCT04125524: Terahertz Metamaterials for Tumour Marker Concentration Identification
Official title: Terahertz Metamaterials for Tumour Marker Concentration Identification
Study type: OBSERVATIONAL
Overall status: SUSPENDED
Conditions: Malignant Tumour
Keywords: Tumour markers
Lead sponsor: Durham University
Sponsor class: OTHER
Collaborators: name: County Durham and Darlington NHS Foundation Trust
First posted: 2019-10-14
Enrollment: 90
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: County Durham and Darlington NHS Foundation Trust

Brief summary: The research the investigators plan to undertake involves the use of a metamaterial at terahertz frequencies. Serum samples will be tested using the metamaterial to determine if this method can be used to measure the concentration of tumour markers present in the sample. Patients who have been tested for CEA, LDH, CA-125, CA 19-9, CA 15-3, total-hCG and AFP will be used for both the positive and negative samples.

Detailed description: The research the investigators plan to undertake involves the use of a paper substrate with a gold metamaterial on top or a plastic substrate with gold metamaterial on top in physical contact with paper. The metamaterial has an absorption peak within the terahertz frequency range to be investigated (0.75 - 1.1THz). The serum samples will be soaked into the paper fibres which will shift the absorption peak within the terahertz frequency range dependent on the concentration of tumour markers present in the sample. The serum samples will be surplus from samples tested for CEA, LDH, CA-125, CA 19-9, CA 15-3, total-hCG and AFP at the Durham and Darlington NHS Fondation Trust. The samples will be anonymised with the exception of which tumour marker they were tested for and the level measured.

There will be two stages to this research project the initial stage requires 15 samples per proposed marker including 15 samples (across all markers) for negative results. This will be used to identify suitable markers to consider for the second stage. Where 50 to 90 samples of each qualifying marker will be tested dependent on the number required for statistical confidence in stage two with 10 to 18 negative samples required for each qualifying marker, again dependent on the statistical requirements for each marker.

Eligibility criteria: Inclusion Criteria:

* Any patient recommended by their health professional to be tested for any of the tumour markers being studied at County Durham and Darlington NHS Foundation Trust for any reason.

Exclusion Criteria:

* Patients with known bloodborne pathogens.

Primary outcomes:
measure: Evidence of detection for any marker
timeFrame: 18 months
Secondary outcomes:
measure: Quantifying the quality of detection per marker
timeFrame: 18 months
Other outcomes:
Locations:
city: Durham
country: United Kingdom
facility: Department of Engineering Durham University
Study officials:
References:
Clinical trial NCT06387524: Effects of Eccentric Exercises on Gait Parameters in Patellofemoral Pain Syndrome: A Quasi-Experimental Study
Official title: Effects of Eccentric Exercises on Gait Parameters in Patellofemoral Pain Syndrome: A Quasi-Experimental Study
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Patellofemoral Pain Syndrome
Lead sponsor: Foundation University Islamabad
Sponsor class: OTHER
First posted: 2024-04-29
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Quasi experimental study
Primary purpose: TREATMENT

Brief summary: This study is a quasi experimental and the purpose of this study is to determine the effects of eccentric exercises on gait parameters in patellofemoral pain syndrome: a quasi - experimental study

Detailed description: The purpose of this study is to determine the effects of eccentric exercises on gait parameters in patellofemoral syndrome : a - quasi experimental study

Pain , gait parameters, ROM and dynamic knee valgus angle of young adults (age : 18-35 years ) will be determined using:

1. Numeric pain rating scale
2. Goniometer
3. 30 meter walk test
4. dynamic knee valgus angle via kinovea software Data will be before and after the intervention protocol for each participant. Data collection procedure: Participants of interest would be approached and explained about the research. Informed written consent will be taken. Pre and post intervention scores will be recorded.

Eligibility criteria: Inclusion Criteria:

* Age 18-35 years
* Females
* Having pain from at least 2 months
* Pain score greater than 3 on NPRS
* Retro patellar pain in at least two of the following activities:

  1. Ascending, descending stairs
  2. Hooping / jumping
  3. Prolonged sitting with flexed knees
  4. Kneeling and squatting
* Pain on palpation of medial or lateral patellar facet.
* Pain on palpation on anterior portion of medial or lateral femoral condyles.

Exclusion Criteria:

* Diagnosed with Chondromalacia patellae
* Instability of tibiofemoral joint
* Subluxation of patellofemoral joint
* Patellar instability
* Previous surgery of lower limb
* Negative findings on examination of knee ligaments, menisci and bursa.

Primary outcomes:
measure: Dynamic knee valgus angle
timeFrame: 6 weeks
measure: Hip Range of Motion
timeFrame: 6 weeks
measure: Knee Range of Motion
timeFrame: 6 weeks
measure: Pain intensity
timeFrame: 6 weeks
measure: Gait Speed
timeFrame: 6 weeks
measure: Cadence
timeFrame: 6 weeks
measure: Stride length
timeFrame: 6 weeks
measure: Step length
timeFrame: 6 weeks
measure: Cycle length
timeFrame: 6 weeks
Secondary outcomes:
Other outcomes:
Locations:
city: Rawalpindi
country: Pakistan
facility: Foundation University College of Physical Therapy
state: Punjab
Study officials:
References:
Clinical trial NCT01470924: Acute Lymphoblastic Leukemia Relapse in Sweden 2003-2007
Official title: High Curability Via Intensive Reinduction Chemotherapy and Stem Cell Transplantation in Young Adults With Relapsed Acute Lymphoblastic Leukemia in Sweden 2003-2007
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Acute Lymphoblastic Leukemia
Keywords: acute lymphoblastic leukemia
relapse
salvage
prognostic
Lead sponsor: Region Örebro County
Sponsor class: OTHER
First posted: 2011-11-11
Enrollment: 76
Sex: ALL
Minimum age (years): 18
Maximum age (years): 66
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: All adults with relapsed ALL

Brief summary: A minority of patients with adult acute lymphoblastic leukemia (ALL) relapse are rescued. The aim of this population-based study was to assess the results of reinduction treatment and allogeneic stem cell transplantation (SCT) in second complete remission (CR) in Sweden 2003-2007.

Detailed description: This is a national, multicenter, prospective, population-based study of outcome among adult patients aged 19 to 65 years with ALL relapse diagnosed during 2003-2007 in Sweden. Most of the patients had primary treatment according to National guidelines for ALL as recommended by The Swedish Adult ALL Group (SVALL). The guidelines suggest two different treatment protocols for early relapses, and retreatment according to the initial therapy for late relapses, with the intention to proceed to allogeneic SCT in CR2 for eligible patients. The aim of the current study was to assess outcome among adult patients after first ALL relapse, and the utilization and efficacy of recommended protocols and of allogeneic SCT in this setting.

Eligibility criteria: Inclusion Criteria:

* Adult patients with first relapse of ALL

Exclusion Criteria:

* patients with Burkitt leukemia

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Orebro
country: Sweden
facility: Orebro University Hospital
state: Orebro County
Study officials:
affiliation: Region Örebro County
name: Piotr J Kozlowski, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01102296: Effectiveness of Hepatitis A Virus Vaccination Among Homosexual Males at Risk for Hepatitis A Infection
Official title: Division of Infectious Diseases, Department of Internal Medicine, National Taiwan University Hospital
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Hepatitis
Keywords: hepatitis A vaccine
male homosexual
HIV infection
male homosexuals who are seronegative for hepatitis A virus
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2010-04-13
Enrollment: 582
Sex: MALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Male homosexuals are at risk for hepatitis A virus (HAV) infection, and HAV vaccination has been recommended to prevent HAV infection in male homosexuals. HIV infection may impair serological responses to HAV vaccination in HIV-infected patients. The investigators hypothesize that 3 doses of HAV vaccine will improve serological responses to HAV vaccine in HIV-infected patients.

Detailed description: In this study, we aim to compare the serological responses to HAV vaccination between HIV-infected patients who receive 2 doses or 3 doses of HAV vaccine and HIV-uninfected persons who receive 2 doses of HAV vaccine. Persons who identify themselves as male homosexuals aged younger than 40 years and are seronegative for hepatitis A virus will be enrolled. HAV vaccination will be provided free-of-charge. HIV-uninfected persons will receive 2 doses of HAV vaccine that will be administered at baseline and 6 months after the first dose, while HIV-infected patients will be given 2 doses or 3 doses of HAV vaccine; for those who choose to receive 3 doses, a second dose will be given 1 month after the first dose. A longitudinal follow-up of serological responses will be conducted to assess the effectiveness of HAV vaccination; HAV IgG will be determined at 6 months after the first dose of HAV vaccination(before the administration of the second dose), 12 months and 18 months after the first dose of HAV vaccination .

Eligibility criteria: Inclusion Criteria:

* Age between 18\~40-years-old
* Homosexuals

Exclusion Criteria:

* Presence of symptoms or signs suggestive of active infection
* Allergy to vaccination
* Failure to provide written informed consent
* Use of immunosuppressive or immunomodulating agents or chemotherapy

Primary outcomes:
measure: the proportion of vaccinees who achieve anti-HAV antibody concentrations of 20 mIU/ml or greater at week 48 of vaccination
timeFrame: 48 weeks
Secondary outcomes:
measure: the concentrations of anti-HAV antibody at week 48 of vaccination
timeFrame: 48 weeks
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
Study officials:
affiliation: Division of Infectious Disease, Department of Internal Medicine, National Taiwan University Hopsital
name: Chien-Ching Hung, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00151996: Safety and Tolerability of SPD503 and Psychostimulants in Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)
Official title: A Phase II, Open-Label Co-Administration Study of SPD503 and Psychostimulants in Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Attention Deficit Disorder With Hyperactivity
Lead sponsor: Takeda
Sponsor class: INDUSTRY
First posted: 2005-09-09
Enrollment: 75
Sex: ALL
Minimum age (years): 6
Maximum age (years): 17
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to assess the safety and tolerability of administering SPD503 (Guanfacine hydrochloride) with psychostimulants (amphetamine or methylphenidate) for treatment of ADHD in children and adolescents aged 6-17


Eligibility criteria: Inclusion Criteria:

* Subjects with a primary diagnosis of ADHD
* Subject on a stable dose of a psychostimulant approved for the treatment of ADHD for at least 1 month, with sub-optimal control in the Investigator's opinion
* Male or non-pregnant female subject who agrees to comply with any applicable contraceptive requirements

Exclusion Criteria:

* Subject has current uncontrolled comorbid psychiatric diagnosis (except ODD and mild anxiety) with significant symptoms
* History of seizure during the last 2 years
* Subject has any specific cardiac condition or family history of significant cardiac condition
* Subject is pregnant or lactating

Primary outcomes:
measure: Change From Baseline in the Attention Deficit Hyperactivity Disorder Rating Scale (ADHD-RS-IV) Total Score at 6 Weeks
timeFrame: Baseline and 6 weeks
Secondary outcomes:
measure: Number of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) Scores
timeFrame: 6 weeks
measure: Change From Baseline in Conner's Parent Rating Scale-revised Short Version (CPRS-R) Total Score at 6 Weeks
timeFrame: Baseline and 6 weeks
measure: Number of Participants With Improvement on Parent Global Assessment (PGA) Scores
timeFrame: 6 weeks
measure: Change From Baseline in Child Health Questionnaire-Parent Form (CHQ-PF50) Scores at 6 Weeks
timeFrame: Baseline and 6 weeks
Other outcomes:
Locations:
Study officials:
affiliation: Takeda
name: Study Director
role: STUDY_DIRECTOR
References:
citation: Spencer TJ, Greenbaum M, Ginsberg LD, Murphy WR. Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2009 Oct;19(5):501-10. doi: 10.1089/cap.2008.0152.
Clinical trial NCT00189696: Phase 3 Study of YM060 in Patients With Diarrhea-predominant Irritable Bowel Syndrome (d-IBS)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Irritable Bowel Syndrome
Keywords: Irritable Bowel Syndrome, Diarrhea
Lead sponsor: Astellas Pharma Inc
Sponsor class: INDUSTRY
First posted: 2005-09-19
Sex: ALL
Minimum age (years): 20
Maximum age (years): 64
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will examine the efficacy, safety and tolerability of oral dose of YM060, 5-HT3 receptor antagonist, in patients with d-IBS.


Eligibility criteria: Inclusion Criteria:

* Patients satisfying the Rome II Diagnostic Criteria.
* Patients in whom no organic changes were observed in large intestine.

Exclusion Criteria:

* Patients have diseases which interfere with evaluation of the efficacy and safety in this study.
* Patients are receiving and/or have received prior to the enrollment the treatment which interfere with evaluation of the efficacy and safety in this study.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Chubu region
country: Japan
city: Kanto region
country: Japan
city: Shikoku region
country: Japan
city: Tohoku Region
country: Japan
Study officials:
affiliation: Astellas Pharma Inc
name: Study Director, Clinical Development III
role: STUDY_CHAIR
References:
citation: Matsueda K, Harasawa S, Hongo M, Hiwatashi N, Sasaki D. A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome. Scand J Gastroenterol. 2008;43(10):1202-11. doi: 10.1080/00365520802240255.
Clinical trial NCT03893396: Safety Assessment of Angioplasty Procedures
Official title: Safety Assessment of Angioplasty Procedures
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Angiospastic; Disorder
Keywords: drug eluting stent
Drug-coated balloon
Bare-Metal Stent
Revascularization
Lead sponsor: Groupe Hospitalier de la Rochelle Ré Aunis
Sponsor class: OTHER
Collaborators: name: BBraun Medical SAS
First posted: 2019-03-28
Enrollment: 983
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients referred for coronary angiography for revascularization are those for whom a diagnosis of acute (Acute Coronary Syndrome with or without ST segment elevation) or chronic (Silent myocardial ischemia, angina) coronary pathology has been made

Brief summary: Ischemic heart disease, or coronary heart disease, covers a set of pathologies due to insufficient oxygen supply to the myocardium due to the development of atherosclerosis in one or more coronary arteries. To evaluate the safety of angioplasty performed in patients operated on at La Rochelle Hospital, the rate of major adverse cardiac events (MACE) will be determined and compared with data from the literature.

Detailed description: The use of active stents for the treatment of coronary stenosis is currently the standard treatment in almost all types of coronary lesions. In percutaneous transluminal treatment of coronary lesions, balloon angioplasty and bare stents have not shown satisfactory results in the past. The so-called active drug-eluting balloon could represent a new therapeutic option for the treatment of de novo lesions.

Eligibility criteria: Inclusion Criteria:

* Interventional revascularization of a coronary lesion,
* Member or beneficiary of a social security system,
* Informed of the study.

Exclusion Criteria:

* Language barrier,
* Minor,
* Pregnant woman,
* Person under guardianship,
* Person deprived of his/her liberty,
* Refusal to participate.

Primary outcomes:
measure: Number of Major Adverse Cardiac Events (MACE)
timeFrame: 12 months
Secondary outcomes:
measure: Number of Major Adverse Cardiac Events (MACE)
timeFrame: 36 months
Other outcomes:
Locations:
city: La Rochelle
country: France
facility: Groupe Hospitalier de la Rochelle Ré Aunis
Study officials:
affiliation: Groupe Hospitalier de la Rochelle Ré Aunis
name: Ludovic MEUNIER, MD
role: STUDY_DIRECTOR
References:
citation: Meunier L, Godin M, Souteyrand G, Mottin B, Valy Y, Lordet V, Benoit C, Bakdi R, Laurencon V, Genereux P, Waliszewski M, Allix-Beguec C. Prospective, single-centre evaluation of the safety and efficacy of percutaneous coronary interventions following a decision tree proposing a no-stent strategy in stable patients with coronary artery disease (SCRAP study). Clin Res Cardiol. 2023 Sep;112(9):1164-1174. doi: 10.1007/s00392-022-02054-7. Epub 2022 Jul 1.